Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of sweroside

A technology of glycosides and drugs, which is applied in the field of glycosides, can solve the problems of unclear effect components and mechanism of action of Qishen Granules, and achieve the effects of inhibiting excessive wall thickening, improving myocardial fibrosis, and promoting recovery

Active Publication Date: 2020-09-08
BEIJING UNIV OF CHINESE MEDICINE
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Qishen granules and others have been confirmed by many studies to be effective in treating heart failure, and the research on the mechanism involves a wide range of research methods, but most of them adopt the overall research idea of ​​compound formula (Li C, Wang J, Wang Q, et al. Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism[J].SciRep,2016,6:36949), the effect components and mechanism of action of Qishen Granules are still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of sweroside
  • New application of sweroside
  • New application of sweroside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Study on drug efficacy of glycosides in treating heart failure

[0047] 1 material

[0048] 1.1 Animals

[0049] SPF grade C57 / BL6N mice, weighing 18-22 g, were provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and the experimental animal license number was SCXK (Beijing) 2016-0006. They were raised in the SPF level animal laboratory of Beijing University of Traditional Chinese Medicine, in a constant temperature and humidity environment, with free drinking water and ordinary feed, and began to model and administer drugs after one week of adaptive feeding.

[0050] 1.2 Reagents

[0051] Dangdaoside was provided by Chengdu Pusi Biotechnology Co., Ltd., batch number: PS0111123. Captopril was purchased from Sino-American Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd., batch number: AAQ3404. Isoproterenol hydrochloride (ISO) was provided by Sigma-Aldrich (Shanghai) Trading Co., Ltd., batch number: 101722747. Sodium potassium...

Embodiment 2

[0080] Example 2: Study on the recovery of myocardial systolic / diastolic function of primary cardiomyocytes in suckling rats when drug glycosides

[0081] 1. Materials

[0082] 1.1 Animals

[0083] SD rat suckling mouse (1d) was purchased from Speiford (Beijing) Biotechnology Co., Ltd., experimental animal license number: SCXK (Beijing) 2016-0002.

[0084] 1.2 Reagents

[0085] Dangdaoside was provided by Chengdu Pusi Biotechnology Co., Ltd., product number 14215-86-2.

[0086] Collagenase Type II was provided by Gibco, USA, with the item number 17101-015.

[0087] Trypsin was provided by VWR-amresco in the United States, the product number was 0458-25G.

[0088] 5-brdu (5-Bromo-2'-deoxyuridine) was provided by Sigma-Aldrich (Shanghai) Trading Co., Ltd., item number B5002.

[0089] DMEM (sugar-free) was provided by Gibco, USA, product number 11966-025.

[0090] DMEM powder was provided by Gibco, USA, the product number is 12100-046.

[0091] D-MEM / F-12 powder is provide...

Embodiment 3

[0141] Example 3: The protective effect of Dangdaoside on isolated heart ischemia-reperfusion injury

[0142] 1. Materials

[0143] 1.1 Animals

[0144] About 250 g of SD rats were purchased from Speifu (Beijing) Biotechnology Co., Ltd., experimental animal license number: SCXK (Beijing) 2016-0002. Raised in the SPF animal laboratory of Beijing University of Traditional Chinese Medicine, constant temperature and humidity, 12h day-night alternation, free drinking water, common feed

[0145] 1.2 Reagents

[0146] Dangdaoside was provided by Chengdu Pusi Biotechnology Co., Ltd., product number 14215-86-2.

[0147] Digoxin is provided by MedChemexpress (MCE) in the United States, the product number is HY-B1049.

[0148] Sodium pentobarbital was provided by Sigma-Aldrich (Shanghai) Trading Co., Ltd., item number P3761-25G.

[0149] Heparin sodium was provided by Beijing Baierdi Biotechnology Co., Ltd., product number DE0290-1g.

[0150] 2% TTC staining solution was provided b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of sweroside in preparation of medicines for treating, preventing, alleviating and / or alleviating diseases related to heart failure. Researches show that the sweroside has the effects of inhibiting excessive thickening of the ventricular wall, delaying myocardial remodeling, improving myocardial fibrosis and improving the cardiac function; and in addition, thesweroside can promote recovery of the contraction / relaxation functions of damaged myocardial cells, and has a protective effect on ischemia-reperfusion injury of heart.

Description

technical field [0001] The present invention belongs to the field of medicine. Specifically, the present invention relates to the new application of glycosides, and more specifically, the present invention relates to the use of glycosides in treating heart failure, promoting the recovery of damaged cardiomyocyte systolic / diastolic function, and improving myocardial ischemia. Novel use in reperfusion injury. Background technique [0002] Heart failure refers to a clinical syndrome in which myocardial structure and function are abnormal due to various reasons, resulting in impairment of ventricular systolic function (ejection) and / or diastolic function (filling). "China Cardiovascular Disease Report 2018" (Ma Liyuan, Wu Yazhe, Chen Weiwei., et al. Introduction to the key points of "China Cardiovascular Disease Report 2018" [J]. Chinese Journal of Hypertension, 2019, 27(08):712-716) , the number of patients with heart failure is as high as 4.5 million, and the prevalence rate ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/06A61P9/00
CPCA61K31/7048A61P9/00A61P9/06
Inventor 王伟刘斌郭淑贞王青苏聪平
Owner BEIJING UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com